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Selection of antigens for therapeutic vaccination against chronic viral infections is
complicated by pathogen genetic variations. We tested whether antigens present during
persistent viral infections could provide a personalized antigenic reservoir for therapeutic T
cell expansion in humans. We focused our study on the HBV surface antigen (HBsAg),
which is present in microgram quantities in the serum of chronic HBV patients. We
demonstrated by quantitative fluorescent microscopy that, out of 6 professional APC
populations in the circulation, only CD14 monocytes (MNs) retained an HBsAg depot. Using
TCR-redirected CD8+ T cells specific for MHC-I–restricted HBV epitopes, we showed that,
despite being constantly exposed to antigen, ex vivo–isolated APCs did not constitutively
activate HBV-specific CD8+ T cells. However, differentiation of HBsAg+ CD14 MNs from
chronic patients to MN-derived DCs (moDCs) induced cross-presentation of the intracellular
reservoir of viral antigen. We exploited this mechanism to cross-present circulating viral
antigen and showed that moDCs from chronically infected patients stimulated expansion of
autologous HBV-specific T cells. Thus, these data demonstrate that circulating viral antigen
produced during chronic infection can serve as a personalized antigenic reservoir to
activate virus-specific T cells.
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Selection of antigens for therapeutic vaccination against chronic viral infections is complicated by pathogen 
genetic variations. We tested whether antigens present during persistent viral infections could provide a per-
sonalized antigenic reservoir for therapeutic T cell expansion in humans. We focused our study on the HBV 
surface antigen (HBsAg), which is present in microgram quantities in the serum of chronic HBV patients. We 
demonstrated by quantitative fluorescent microscopy that, out of 6 professional APC populations in the cir-
culation, only CD14 monocytes (MNs) retained an HBsAg depot. Using TCR-redirected CD8+ T cells specific 
for MHC-I–restricted HBV epitopes, we showed that, despite being constantly exposed to antigen, ex vivo–
isolated APCs did not constitutively activate HBV-specific CD8+ T cells. However, differentiation of HBsAg+ 
CD14 MNs from chronic patients to MN-derived DCs (moDCs) induced cross-presentation of the intracellular 
reservoir of viral antigen. We exploited this mechanism to cross-present circulating viral antigen and showed 
that moDCs from chronically infected patients stimulated expansion of autologous HBV-specific T cells. Thus, 
these data demonstrate that circulating viral antigen produced during chronic infection can serve as a person-
alized antigenic reservoir to activate virus-specific T cells.
Introduction
Therapeutic vaccination for chronic infections, be it recombinant 
antigens, peptides, viral vectors, DNA, or DCs, are hindered by 
the need to select appropriate antigens. It is a major complicat-
ing factor due to the evolutionary diversity that pathogens have 
developed in response to selective forces exerted by individual 
(immune response) or environmental (drugs, vectors) factors. 
Moreover, peptides covering conserved regions for vaccination are 
HLA restricted and can only be applied to selected patients with 
the appropriate HLA. As a result, recombinant antigens or DNA 
vectors coding pathogen proteins may misdirect the intended 
immune response due to differences between the infectious patho-
gen and the antigen sequence utilized for vaccination.
A hallmark of many chronic infections is the constant production 
of pathogen proteins. This is particularly evident in HBV infection, 
where viral titers can reach 109–1010 virions/ml in the serum. The 
HBV surface antigen (HBsAg) is produced in excess of whole virions 
and reaches concentrations well into the μg/ml range (1). While 
persistently present viral antigen is generally considered a negative 
factor (2), the abundance of endogenously produced viral antigen 
could be internalized by different cell types. Proper activation of 
cells internalizing antigen in the circulation of chronic patients 
could provide a target for therapeutic vaccination and stimulate T 
cells with antigen customized to the patient’s viral genome.
HBV does not infect or productively replicate in human PBMCs 
(3), and systematic analysis of cells capable of internalizing circu-
lating viral antigen has not been performed. However, HBsAg par-
ticles are highly immunogenic, and DCs and macrophages from 
mice cross-present recombinant HBsAg (rHBsAg) particles to CD8+ 
T cells in the absence of inflammatory signals (4–7). HBsAg-specific 
B cells can present antigen captured through the B cell receptor via 
the MHC-I pathway (8). The core antigen (HBcAg) has been shown 
to bind membrane Ig on a high frequency of resting B cells and to 
activate CD8+ T cells (9). These studies have been performed in mice 
or in vitro model systems and demonstrate that HBV antigens have 
the ability to activate HBV-specific CD8+ T cells, which play a key 
role in HBV control (10). Yet, there is no answer as to whether APCs 
are capable of internalizing antigen in the circulation of patients 
and, more importantly, whether naturally sequestered antigen can 
be presented to activate virus-specific CD8+ T cells in humans.
The aim of our study was to determine whether circulating viral 
antigen can be exploited to activate virus-specific T cells. Because 
multiple cell types cross-present HBV antigens in model systems, 
we took a comprehensive approach and used FACS to isolate 6 
highly purified populations of DCs, MNs, and B cells ex vivo from 
chronic HBV patients. We tested the different APCs for the pres-
ence of viral antigen captured from the circulation and to deter-
mine whether persistent antigen could be cross-presented and 
used to activate autologous virus-specific T cells.
Results
Professional APC frequency and function in chronic HBV patients. Con-
troversy exists in chronic HBV infection as to whether the frequen-
cy and function of APCs is intact. Therefore, before investigating 
questions related to antigen-specific T cell activation in the circu-
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lation, we characterized the APC compartment in 28 chronic HBV 
patients (Supplemental Table 1; supplemental material available 
online with this article; doi:10.1172/JCI66043DS1). Analysis of the 
frequency of total APCs (HLA-DR+) or 7 distinct APC populations 
ex vivo (Figure 1A; myeloid DCs [mDCs], CD141 DCs, CD123 
plasmacytoid DCs (pDCs), CD14 monocytes [CD14 MNs], CD14/
CD16 MNs, CD16/CD14 low MNs [CD16 MNs], and CD20 B 
cells) did not show any significant differences between chronic 
HBV patients and healthy controls (Figure 1B). The frequency of 
APCs was not altered by viral load (Supplemental Figure 1) or liver 
inflammation (Supplemental Figure 2). We did find that the fre-
quency of CD14 MNs tended to be lower in chronic HBV patients, 
while the frequency of CD20 B cells tended to be increased, but 
these differences were not significant.
We tested the stimulatory capacity of 4 of the APC populations 
using allogeneic mixed lymphocyte reactions (MLR) where suffi-
cient numbers could be consistently obtained. The division index 
and proliferation index were calculated for T cells after coculture 
with sorted APCs. Similar to their frequency, we did not observe 
any significant differences in the ability of professional APCs from 
chronic HBV patients (Supplemental Table 2) to stimulate prolif-
eration compared with healthy donors (Figure 2). This suggests 
that at least these 4 APC populations from chronic HBV patients 
are not inherently inhibitory.
HBsAg in ex vivo–isolated APCs. Having shown that the frequen-
cy and function of APCs was generally intact in our cohort of 
chronic HBV patients, we began to investigate whether circulating 
HBV antigen could be internalized by APCs in the blood. Previ-
ous reports demonstrated the presence of HBV in DCs using PCR 
and electron microscopy (3, 11). However, due to the sensitivity of 
these assays and limited quantitative data from electron micros-
copy, controversy remains as to whether it is accurate or due to 
trace contamination with serum or cells. To clarify this issue, we 
sorted 6 APC populations, stained them for HBsAg, and analyzed 
the cells using the Tissuefax system, as it allows for quantitative 
analysis of fluorescent microscopy data.
Only CD14 MNs in the circulation of chronic patients stained 
positive for HBsAg; CD16 MNs, mDCs, CD141 DCs, pDCs, and B 
cells were negative, with background similar to what is observed in 
healthy controls (Figure 3, A and B). CD14 MNs were positive for 
Figure 1
APC gating strategy and population frequency analysis in healthy donors and chronic HBV patients. (A) Lineage-negative (CD3/CD56/CD7) HLA-DR+ 
APCs were derived from total live PBMCs gated by forward and side scatter followed by single-cell gating using width and height parameters 
with viability dye (data not shown). CD11c mDCs, CD141 DCs, CD123 pDCs, and CD20 B cells were identified from the CD14/CD16 double-
negative population. (B) Frequency of HLA-DR+ cells in total PBMCs and frequency of specific APC populations as a proportion of HLA-DR+ 
cells. There were no statistically significant differences determined by 1-way ANOVA and Tukey’s post-test analysis using total CHB patients; 
information on patients categorized by viral load and liver inflammation is displayed in Supplemental Figures 1 and 2.
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HBsAg in 12 out of 19 patients tested (Supplemental Table 3). The 
frequency of HBsAg+ CD14 MNs ranged from 20% to 96% with 
a mean of 43% (Figure 3C). Similar to the representative patient 
shown, CD16 MNs, mDCs, CD141 DCs, pDCs, and B cells were 
negative for HBsAg after screening multiple patients (Figure 3C). 
Thus, CD14 MNs are the only cell population carrying a detectable 
depot of viral antigen in the circulation of chronic HBV patients.
Since HBsAg+ CD14 MNs were not detectable in all patients (n = 7), 
we determined whether HBsAg staining in CD14 MNs correlated 
with viral parameters (HBV DNA and HBsAg). In the 12 patients 
that showed HBsAg staining in CD14 MNs, higher viral load cor-
related with higher frequencies of HBsAg+ CD14 MNs (Figure 3D). 
However, this was inconsistent because some patients with low 
viral load (<103) showed HBsAg+ CD14 MNs similar to those with 
HBV-DNA levels of 104–105 (Figure 3D). Furthermore, HBsAg-
negative CD14 MNs were found in patients with HBV DNA similar 
to those that stained positive (data not shown). We also observed 
that a 3 log10 drop in viral load in a patient on antiviral therapy did 
not influence HBsAg staining, all suggesting that HBsAg positivity 
is not directly related to viremia (Figure 3E).
We then analyzed whether only HBsAg levels directly correlate 
with HBsAg+ staining in CD14 MNs. We selected 5 patients under 
antiviral therapy in which HBV DNA values were negative by clini-
cal testing but who had increasing levels of HBsAg in the serum. 
A dose-dependent increase in HBsAg+ CD14 MNs occurred as 
HBsAg increased in the circulation (Figure 3F), confirming that 
detection of HBsAg+ CD14 MNs is directly related to the level of 
circulating viral antigen. Staining became maximal at approxi-
mately 3306 IU/ml HBsAg (equivalent ≈ 18.5 μg/ml). The low-
est concentration tested, 606 IU/ml (≈3.3 μg/ml), was just above 
background staining (data not shown), indicating that the detec-
tion threshold for HBsAg staining has a cutoff of roughly 3 μg/ml 
HBsAg in the serum.
Testing ex vivo MHC-I presentation by APCs using HBsAg-specific redi-
rected T cells. Next, we investigated whether in vivo–captured HBsAg 
can be constitutively presented on HLA-class I to HBV-specific 
CD8+ T cells. We used TCR gene transfer to engineer HBV-specific 
T cells (12). Lymphocytes of healthy donors were transduced with 
HLA-A2 or HLA-Cw08 restricted HBsAg-specific TCRs and used 
to detect MHC-I antigen presentation in all subsequent functional 
assays (Supplemental Figure 3).
We sorted APCs from 7 chronic HBV patients and 4 healthy 
donors (Supplemental Table 4). Purified APCs were cocultured 
with appropriately matched, HLA-restricted HBsAg-specific TCR-
redirected T cells. T cell activation, measured by IFN-γ production, 
was used to determine whether ex vivo APCs isolated from chronic 
HBV patients presented HBsAg epitopes on MHC-I. Coculture 
with APCs of either healthy donors or chronic HBV patients ex 
vivo did not stimulate any significant T cell IFN-γ production as 
measured by IFN-γ ELISPOT (Figure 4). The negative results were 
confirmed using flow cytometry to monitor T cell IFN-γ produc-
tion (data not shown). We then determined whether inflammatory 
stimuli (adjuvants) could induce the cross-presentation of in vivo–
captured antigen by ex vivo–isolated APCs. Sorted mDCs, CD14 
MNs, CD16 MNs, or B cells were activated with TLR-3, -4, and -9 
ligands, IFN-α, or IFN-γ and cocultured with HBsAg-specific TCR-
transduced T cells. Similarly, under these conditions, we did not 
observe any T cell activation, indicating that even after short-term 
activation, mDCs, CD14 MNs, CD16 MNs, or B cells did not cross-
present circulating HBsAg (Figure 4A).
Three chronic HBV patients had sufficient cell numbers to 
directly test cross-presentation by CD141 DCs and pDCs. pDCs 
have been shown to cross-present apoptotic debris or lipopro-
teins following TLR-7 or influenza stimulation (13, 14). CD141 
DCs have recently been described as the human equivalent of 
the murine CD8α subset, capable of efficiently cross-presenting 
Figure 2
T cell proliferation following coculture with chronic HBV patient APCs. (A) Frequency of T cells induced to proliferate with each APC population in 
healthy subjects or different HBV cohorts (HBV high [hi] > 106 copies/ml; HBV low ≤ 106 copies/ml; flare ALT > 500 U/l). (B) Normalized proliferation 
index with each APC population. Five patients were tested in each cohort. There were no statistically significant differences.
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antigen in humans after activation by poly(I:C) (15–18). Neither 
resting pDCs nor pDCs activated with a panel of TLR ligands and 
IFN-α activated HBsAg-specific T cells ex vivo (Figure 4B). Fewer 
conditions were tested with CD141 DCs due to the limited cell 
numbers, but neither nonactivated nor poly(I:C)-activated CD141 
DCs from chronic HBV patients stimulated CD8+ T cells directly 
ex vivo (Figure 4C). However, CD141 DCs, unlike pDCs, efficiently 
cross-presented rHBsAg (sAg) loaded exogenously when stimulat-
ed with poly(I:C) (Figure 4, B and C).
Thus, no constitutive or inducible ex vivo cross-presentation of 
HBsAg was detected in the 6 different APC populations tested. T 
cells and APCs were functional as peptide-loaded APCs of chron-
ic patients stimulated T cell IFN-γ production at a level similar 
to those of healthy donors (Figure 4 and data not shown). More-
over, the ability of CD141 DCs to cross-present soluble antigen 
was not altered by HBV persistence. We also tested whether HBV 
core antigen (HBcAg) was presented to HLA-A2–restricted CD8+ 
T cells ex vivo utilizing HBcAg-specific TCR redirected (c18-TCR) 
Figure 3
HBsAg staining in FACS-sorted APC populations. (A) Representative fluorescent microscopy images of 6 different APCs sorted from a chronic 
HBV patient and stained for HBsAg (green) and DAPI (blue). Original magnification, ×20. (B) Dot plot showing quantitative data derived from 
fluorescent images of each cell population acquired on Tissuefax system. TissueQuest 3.0 was used to analyze each cell (DAPI+ event) for the 
presence of HBsAg (FITC+ event). Dot plots for 1 representative chronic HBV patient (CHB; top row) and 1 healthy donor (bottom row) are pre-
sented. (C) Compilation of the frequency of HBsAg+ cells from multiple patients for each APC population. (D) Frequency of HBsAg+ CD14 MNs 
plotted against viral load in 12 patients with HBsAg+ CD14 MNs. (E) HBsAg staining in a patient under antiviral therapy. Longitudinal analysis did 
not show any reduction in HBsAg staining despite a 3 log10 decrease in viral load. (F) CD14 MNs stained for HBsAg from patients with undetect-
able HBV DNA and known HBsAg quantities.
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T cells. Similar to HBsAg-specific T cells, we did not observe any 
T cell activation with APCs from 4 HLA-A0201 chronic HBV 
patients (data not shown). Therefore, even though the major 
populations of APCs in the circulation of chronic HBV patients 
are constantly exposed to viral antigen (HBsAg and HBcAg), 
they do not constitutively process and present the antigen via 
the MHC-I pathway to CD8+ T cells.
Cross-presentation of in vivo–captured HBsAg by MN-derived DCs from 
patients. Since CD14 MNs are the predominant HBsAg+ APC pop-
ulation, we hypothesized that their differentiation to DCs could 
permit cross-presentation of captured HBV antigens. We initially 
tested this by loading healthy donor CD14 MNs with increasing 
amounts of rHBsAg at day 0 (Figure 5A). The CD14 MNs were dif-
ferentiated to MN-derived DCs (moDCs) with GM-CSF and IL-4, 
and cross-presentation was monitored using TCR-redirected CD8+ 
T cells. Differentiation alone resulted in dose-dependent cross-
presentation of HBsAg to virus-specific CD8+ T cells, which was 
enhanced with moDC activation (Figure 5B).
We then tested whether viral antigen naturally captured by CD14 
MNs from the patient circulation in vivo can be presented to T 
cells after ex vivo DC differentiation. Purified CD14 MNs from 
14 chronic HBV patients (Supplemental Table 5) were stained for 
HBsAg ex vivo to determine their antigen content and differenti-
ated to moDCs for 6 days in the presence of IL-4 and GM-CSF. 
Cross-presentation of in vivo–captured HBsAg was monitored 
using TCR-redirected CD8+ T cells. moDCs from 5 HLA-A0201+ 
chronic patients were tested with HLA-A0201–restricted 
HBs183-91 epitope–specific T cells, while moDCs derived from 
4 HLA-Cw0801+ chronic patients were tested with HLA-Cw0801-
restricted HBs171-80 epitope–specific T cells. moDCs from 5 
HLA-mismatched chronic HBV patients and 3 HLA-matched 
healthy donors served as negative controls.
Ex vivo HBsAg staining of CD14 MNs was observed in 7 out of 9 
HLA-matched patients and in all 5 HLA-mismatched patients 
(Figure 6A). Only 1 patient, chronic HBV–8 (CHB-8), showed 
HBsAg staining following differentiation to moDCs (data not 
shown). Upon differentiation alone, robust T cell activation was 
detected in 6 of 9 HLA-matched chronic HBV patients (Figure 6B). 
moDCs from HLA-matched healthy subjects or HLA-mismatched 
chronic HBV patients did not stimulate any significant T cell acti-
vation (Figure 6B). Activation of moDCs resulted in increased T 
cell responses; with a total of 8 of 9 moDCs derived from HLA-
matched chronic HBV patients able to elicit a positive T cell 
response (Figure 6C). Activation of HLA-matched healthy or HLA-
mismatched moDCs from chronic patients did not result in any 
significant increase in HBV-specific T cell activation.
We did observe variability in responses. Patient CHB-6 did not 
show any HBsAg staining in CD14 MNs ex vivo, but was capable 
of activating HBs183-91–specific T cells upon moDC differentia-
tion, suggesting that HBsAg levels of 3 μg/ml and below (limit 
of our HBsAg staining assay) can be efficiently cross-presented. 
Conversely, patient CHB-9, with HBsAg+ CD14 MNs was unable 
to trigger HBV-specific T cells, perhaps due to the presence of 
an escape mutation in the HBV epitope. In contrast, CHB-8, the 
one patient with detectable HBsAg in moDCs following differ-
entiation, showed the greatest T cell response upon activation 
with poly(I:C). Taken together, these data show that it is possible 
to differentiate HBsAg+ CD14 MNs from the blood of chronic 
HBV patients and harness the sequestered viral antigen to activate 
virus-specific CD8+ T cells.
Expansion of autologous virus-specific T cells using moDCs presenting 
in vivo captured HBsAg. Finally, we determined whether cross-pre-
sentation of in vivo–captured antigen by moDCs could be used to 
expand autologous HBV-specific T cells in chronic HBV patients. 
HBV-specific T cells are functionally and numerically impaired in 
chronic HBV patients (19), but can still be detected in low num-
bers in young adults (20), patients under anti-viral therapy (21), or 
those with low HBV-DNA (22). We tested 20 patients (Supplemen-
tal Table 6), 16 under antiviral therapy and an additional 4 that 
were treatment naive (CHB-29-32). We isolated CD14 MNs from 
each patient and differentiated them to moDCs with GM-CSF 
plus IL-4. The moDCs were activated with LPS plus CD40L and 
cocultured with autologous PBMCs for 10 days, relying only on 
in vivo–captured antigen to expand virus-specific T cells. In paral-
lel, PBMCs were expanded using a standard approach with 15-mer 
overlapping peptides covering HBsAg and HBcAg to compare 
responses between the 2 methods.
As expected (19), isolated patient cells did not exhibit virus spe-
cific responses ex vivo (data not shown). T cells specific for both 
HBcAg and HBsAg could instead be expanded in 16 patients after 
Figure 4
No detectable constitutive or inducible ex vivo cross-presentation. S183-TCR T cell IFN-γ ELISPOT following overnight coculture with (A) mDCs, 
CD14 MNs, CD16 MNs, and B cells; (B) pDCs; (C) CD141 DCs sorted from a representative chronic HBV patient. APCs were left untreated (Ø) 
or activated overnight with TLR ligands, IFN-α, or IFN-γ, then cocultured with s183-TCR T cells. All cell types were able to present exogenously 
added peptide. Data in A are representative of 7 patients; data in B and C are representative of 3 patients.
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10 days of in vitro culture with synthetic peptide pools (Figure 7A). 
More importantly, PBMCs expanded with GM-CSF + IL-4 moDCs 
(GM/4-DCs), presenting in vivo captured HBV antigen, resulted 
in HBV-specific T cell expansion in 6 of 20 patients (Figure 7B). 
Expansion of virus-specific T cells was not only restricted to circu-
lating HBsAg, but also resulted in the expansion of HBcAg-specific 
T cells. No T cell responses to HBV polymerase or X proteins were 
detected (data not shown). These data suggest that, in addition to 
HBsAg, either HBeAg, the soluble form of HBcAg, or HBcAg inter-
nalized as part of whole virions can be processed and presented to 
expand virus-specific T cells.
Fewer responses were observed with GM/4-DCs compared with 
peptides. Boosting virus-specific T cell expansion with GM/4-DCs 
by blocking PD-L1 and CTLA-4 or inhibiting Bim-mediated apop-
tosis, 2 pathways known to increase HBV-specific T cell responses 
(23, 24), was ineffective (data not shown). We then tested whether 
the moDC differentiation program would affect virus-specific T 
cell expansion to determine whether (a) there is flexibility in how 
CD14 MNs can be induced to cross-present antigen and (b) wheth-
er different types of moDCs might be more efficient at expanding 
autologous T cells. moDCs made with GM-CSF + IL-15 have been 
shown to be highly efficient at activating CD8+ T cells (25). There-
fore, we compared the ability of GM/4-DCs and GM-CSF + IL-15 
(GM/15-DCs) moDCs to expand virus-specific T cells in 14 CHB 
patients. Figure 7C shows that HBV-specific T cells were expand-
ed in 7 of 14 patients by GM/15-DCs and that GM/15-DCs did 
enhance T cell responses compared with GM/4-DCs in 6 patients 
(CHB-5, -14, -18, -26, -28, -31).
The moDC-expanded T cells were functionally characterized 
with intracellular cytokine staining. moDCs presenting the in vivo 
captured antigen were capable of expanding both CD8+ (Figure 7D) 
and CD4+ (Figure 7E) T cells. However, these cells displayed an 
exhausted functional phenotype and produced only IFN-γ, but not 
TNF-α or IL-2 (data not shown).
The specificity of the T cells expanded by DCs largely overlapped 
with that of PBMCs expanded with synthetic peptides (Figure 7A). 
However, patients CHB-25, -26, and -28 did show an HBV-specific 
T cell response in the absence of any positive responses with pep-
tides. We do not have enough data to make any firm conclusions, 
but this response could be due to differences between the consen-
sus synthetic peptides and the endogenous antigen presented by 
moDCs. Overall, these data confirm that the depot of viral antigen 
present in circulating MNs can serve as a personalized antigenic 
reservoir to expand autologous virus-specific T cells.
Discussion
The aim of our study was to determine whether persistent antigen 
present during chronic viral infection could serve as a personalized 
antigenic reservoir to activate antigen-specific T cells for potential 
therapeutic intervention. The persistent presence of high quanti-
ties of virions and viral antigens in the circulation of patients with 
chronic hepatitis B has been associated with the immunological 
alterations present in these patients. Specifically, that persistent 
exposure to HBV and HBsAg alters the frequency and function 
of myeloid, plasmacytoid, and moDCs (11, 26–35). The previous 
reports regarding the HBsAg inhibitory effects were largely relat-
ed to TLR-mediated cytokine production and could affect innate 
immunity pathways. However, our analyses of the T cell stimula-
tory function of different APCs ex vivo did not show any signifi-
cant alterations. Despite marked heterogeneity between different 
subjects, we did not find any significant quantitative alterations 
in circulating MNs, DCs, or B cells. The APCs of chronic patients 
stimulated T cell proliferation in MLR reactions, efficiently acti-
vated HBV-specific T cells when loaded with synthetic peptides, 
and preserved, as in the case of CD141 DCs, their cross-presenta-
tion capacity. Combined with the data demonstrating that cross-
presentation could be induced in MNs upon differentiation to 
DCs suggests that antigen processing and presentation are not 
affected in chronic HBV patients. Therefore, the circulating viral 
antigen does not alter the functionality of different APCs. To the 
contrary, circulating antigen selectively captured by CD14 MNs 
can be used to our advantage as a personalized antigenic reservoir 
to activate virus-specific T cells in chronic HBV patients.
Circulating HBsAg was undetectable in 5 out of 6 APC popula-
tions tested, but was internalized and retained at detectable levels 
selectively by CD14 MNs. Our staining showed that the frequency 
of HBsAg+ CD14 MNs did not change significantly with antivi-
ral therapy, which reduced viral load, but was directly correlated 
with the amount of circulating HBsAg in chronic patients. How-
ever, due to the detection threshold of our assay, we were unable 
to effectively visualize HBsAg+ CD14 MNs ex vivo below 3 μg/ml 
HBsAg in the serum. Our detection threshold did not reach the 
sensitivity of our T cell assays, where we observed T cell activation 
by moDCs derived from HBsAg-negative CD14 MNs from chron-
ic patients, suggesting that naturally captured antigen below our 
Figure 5
Cross-presentation by healthy donor moDCs loaded prior to differentia-
tion. (A) Isolated CD14 MNs were loaded with increasing concentrations 
of rHBsAg for 4 hours prior to differentiation and stained for HBsAg to 
confirm uptake. (B) Differentiated moDCs that were loaded at 0 days 
were cocultured with s183-TCR CD8+ T cells ± LPS/CD40L activa-
tion, and cross-presentation was monitored by T cell activation in IFN-γ 
ELISPOT. Data represent the mean of duplicate wells. This is a repre-
sentative graph from 3 healthy donors tested in 4 separate experiments.
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detection limit is also efficiently processed. We were surprised that 
only CD14 MNs stained positive for HBsAg. It is possible that cir-
culating DCs degrade viral antigen rapidly, preventing accumula-
tion to levels detectable by fluorescent microscopy, or that APCs 
cross-presenting HBV antigens in the circulation are eliminated by 
endogenous virus-specific T cells.
Nevertheless, we did not find direct ex vivo evidence for consti-
tutive or inducible cross-presentation in the circulation. These 
results strongly suggest that the virus-specific T cell exhaustion 
seen during persistent HBV infection in patients is not due to 
repeated systemic activation mediated by circulating APCs. Rather, 
T cell exhaustion is likely the result of persistent presentation of 
viral antigen in the liver by infected hepatocytes and nonclassi-
cal APCs, similar to what has been demonstrated in mice (36–38). 
However, we cannot rule out the impact that inflammatory condi-
tions might have on circulating CD14 MNs. Circulating MNs are 
precursors for inflammatory DCs. It has been demonstrated that 
acute viral infections such as influenza cause rapid differentiation 
of blood MNs to mature DCs (39). This could lead to presentation 
of the antigen depot and affect the HBV-specific immune response 
or pathogenesis of chronic HBV infection. Whether this actually 
occurs and whether this would be advantageous or deleterious 
remains to be determined.
While there was no ex vivo cross-presentation, we clearly show 
that the antigen stored in CD14 MNs of chronic HBV patients 
could be efficiently presented to virus-specific CD8+ T cells upon 
DC differentiation. Even more important, presentation of circulat-
ing antigen by moDCs could trigger the expansion of autologous, 
HBV-specific T cells present in chronic HBV patients. MNs have 
been shown to capture systemic antigen in mice and activate CD4+ 
T cells but (40), to our knowledge, this is the first demonstration 
that persistent antigen present in chronically infected patients can 
be utilized to stimulate their own virus-specific T cells. The caveat 
to exploiting this approach in chronic HBV patients is the level of 
exhaustion present in the virus-specific T cell compartment. After 
years of exposure to high levels of viral antigen, T cells either dis-
play an exhausted phenotype (23, 24, 41, 42) or are deleted (22, 43). 
However, recent data has shown that younger patients (<30 years) 
still possess HBV-specific T cells (20) and long-term antiviral thera-
py can, at least partially, restore HBV-specific T cells in adults (21). 
Therefore, applying this approach in patients under successful 
antiviral therapy would likely be the best route to expanding endog-
enous T cells using circulating antigen captured by CD14 MNs.
The magnitude of HBV-specific T cell expansion in the autolo-
gous moDC experiments was variable among the different patients 
and lower relative to peptide-expanded cells. This suggests that the 
Figure 6
moDCs from patients cross-present in vivo 
captured HBsAg. (A) HBsAg staining in CD14 
MNs isolated from chronic HBV patients. (B) 
Cross-presentation of circulating in vivo–cap-
tured HBsAg following coculture of s183-TCR 
and s171-TCR CD8+ T cells with differentiated 
moDCs in the absence of activation. Healthy 
donor and HLA-mismatched chronic HBV 
patient moDCs served as negative controls. 
Positive responses in HLA-matched moDCs 
are shown in black. (C) Activation of moDCs 
can increase the T cell response. moDCs 
were activated overnight with poly(I:C) or LPS 
+ CD40L and then cocultured with s183-TCR 
and s171-TCR CD8+ T cells.
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Figure 7
Expansion of autologous T cells by moDCs presenting in vivo–captured antigen. (A) IFN-γ ELISPOT for chronic HBV patient virus-specific T 
cells expanded with pools of synthetic peptides covering HBcAg (1 pool = core, 42 peptides) and HBsAg (2 pools = Env1 and Env2; 42 peptides 
each). Data displayed as fold above background to normalize variation among patients due to varying background for each assay. Positive cutoff 
was greater than 10 spots and 2 times the background. (B) IFN-γ ELISPOT for chronic patient virus-specific T cells after expansion with moDCs 
made using GM-CSF + IL-4. (C) IFN-γ ELISPOT for chronic patient virus-specific T cells after expansion with moDCs made using GM-CSF + 
IL-15. Positive responses for moDCs were defined as greater than 2 times the average of unstimulated wells and 10 or more spots. Background 
and responses for the moDC assays were lower than in peptide-expanded cultures and thus are presented as IFN-γ spots/105 cells. Intracellular 
cytokine staining to confirm (D) CD8+ and (E) CD4+ HBV-specific T cell expansion with moDCs presenting in vivo captured antigen. Cytokine 
staining shows responses from 2 separate patients and is representative of 4 patients where responses could be detected by intracellular stain-
ing. *Positive response; nt, not tested.
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(BDCA3; Miltenyi Bitotec); and CD123 PerCp-Cy5.5 (Biolegend) for 
30 minutes at 4°C. Viability dyes, DAPI or Live/Dead Yellow Fixable Stain 
(Invitrogen), were used to gate on live cells followed by singlet gates. Cells 
were sorted on BD FACSAria III to greater than 98% purity. Data gener-
ated from the sorting files were used to calculate the frequency of APC 
populations in all subjects.
MLR. Sorted APC populations from healthy donors and chronic HBV 
patients were cocultured with cryopreserved total T cells isolated from a 
single healthy donor using RosetteSep Human T Cell Enrichment Cocktail 
(StemCell Technologies). T cells were labeled with CFSE (Invitrogen) and 
added at a 20:1 effector/target ratio (100,000 T cells:5,000 APCs) to sorted 
APCs and cultured for 7 days in AIM-V medium supplemented with 2% 
human AB serum (Invitrogen). T cells alone served as negative control, and 
T cells plus anti-CD3/anti-CD28 beads served as positive control. After 
7 days, cells were stained with anti–CD3-Horizon V450 (BD Biosciences) 
and acquired on a BD LSR-II flow cytometer. Resulting data were then 
analyzed using the FlowJo Proliferation Platform to determine the division 
index and proliferation index of each APC population from healthy donors 
and chronic HBV patients. The division index is the average number of cell 
divisions that a cell in the original population has undergone. This is an 
average even for cells that never divided. The proliferation index was used 
to compare between patients and is defined as the average number of cell 
divisions that the responding cells underwent.
HBsAg staining. APCs were sorted from chronic HBV patients as described 
above for fluorescent microscopy analysis. Sorted APCs were fixed with 1% 
paraformaldehyde for 15 minutes at room temperature. Fixed cells were 
then blocked with 0.25% saponin in PBS, 2% BSA, 5% goat serum (Serotec) 
for a minimum of 30 minutes and stained with polyclonal anti–HBsAg-
biotin (4.5 μg/ml; Ad/Ay; Abcam) for 1 hour at room temperature. Cells 
were washed 2 times with PBS/1% BSA/0.1% saponin and then stained with 
streptavidin-FITC or streptavidin-APC (BD Biosciences) for 30 minutes 
at room temperature. After 2 washes, cells were loaded onto Superfrost 
Plus Adhesion or Polysine slides (Thermo) and mounted with Prolong 
Gold Antifade + DAPI (Invitrogen), sealed, and acquired on a Tissuefax 
system (TissueGnostics). The Tissuefax system collects a digital image of 
the cytospin cells and calculates the intensity of FITC (HBsAg) fluores-
cence on DAPI-positive cells to give quantitative data on the frequency 
of HBsAg+ cells in the APC population. FITC was chosen as the readout 
channel because this was used to gate out lineage CD3, CD7, and CD56 
markers. Therefore, there were no FITC-positive markers on the APC popu-
lations. CD14 MNs were also sorted by single color staining using PeCy7 
CD14 and isolated using CD14 microbeads to confirm that HBsAg stain-
ing was specific and not an artifact of the 9-color sorting panel. The rela-
tively low quantity of HBsAg required a 2-step biotin-streptavidin staining 
and long exposure times (250–350 ms). As a result, autofluorescence and 
background staining were higher in CD14 MNs and reached up to 15% 
in some healthy donors. TissueQuest 3.0 was used to analyze fluorescent 
microscopy data, with a minimum of 25 fields of view analyzed for each 
cell population to obtain sufficient numbers for analysis.
Ex vivo antigen presentation assays. Sorted APC populations were as follows: 
CD11c DCs, CD141 DCs, CD123 pDCs, CD14 MNs, CD16 MNs, and CD20 
B cells were cultured overnight in medium alone or under activating condi-
tions ± 10 μg/ml rHBsAg (provided by DynaVax). Cells were activated with 
10 μg/ml poly(I:C) (TLR-3), 5 μM CpG ODN2216 (TLR-9), 1 μg/ml LPS 
(TLR-4), 5 μg/ml Imiquimod (TLR-7), 1 μg/ml ssRNA40 (TLR-8) (Invivo-
Gen), 1000 U/ml IFN-α, or 1000 U/ml IFN-γ (R&D systems). Following over-
night incubation, APC populations were thoroughly washed and transferred 
to anti–IFN-γ coated ELISPOT plates and cocultured with CD8+ s183-TCR 
or s171-TCR redirected T cells at a 5:1 effector/target ratio (normally 5,000 
APCs/well but as low as 1000 CD141 DCs/well) for 24 hours. APCs pulsed 
capacity of moDCs to stimulate autologous HBV-specific T cells 
can be further augmented. Our attempts to achieve this by block-
ing PD-L1 and CTLA-4 or using drugs inhibiting Bim-mediated T 
cell apoptosis failed to boost T cell expansion. In contrast, the dif-
ferentiation programs used to make moDCs did appear to affect 
the expansion of HBV-specific T cells. GM/15-DCs have been 
shown to efficiently activate CD8+ T cells (25) and induce respons-
es in a higher frequency of patients than GM/4-DCs, which has 
also been observed in other studies (44). Thus, there may be a 
level of flexibility in how MNs can be targeted to efficiently har-
ness their antigenic depot. We also have to consider that the ex 
vivo experiments remove CD14 MNs from their source of antigen, 
inherently limiting the number of peptide–MHC-I complexes that 
moDCs can present after differentiation. These experiments also 
do not account for the ability of DCs to prime new T cell respons-
es, something that may be possible in vivo but will not be evident 
after 10 days of in vitro expansion. Therefore, our data demon-
strate the potential of this strategy but could result in underesti-
mation of the effect of successfully targeting CD14 MNs in vivo.
The mechanism by which MNs are mobilized to cross-present 
their antigenic depot is under investigation. We simply showed that 
CD14 MNs are positive for HBsAg ex vivo by fluorescent micros-
copy, but future studies will investigate where this antigen depot 
resides. The location of antigen within early or late endosomes can 
have a dramatic impact on the efficiency of cross-presentation (45), 
and this could be related to why alternate differentiation programs 
result in different levels of autologous T cell expansion. How the 
antigen traffics and is handled upon differentiation will be impor-
tant to understanding the molecular mechanism (46) and could 
allow for further optimization of this approach.
Ultimately, we believe we have identified a previously unrecog-
nized function of CD14 MNs during chronic HBV infection. This 
strategy may be extended to other persistent infections and poten-
tially open new avenues for immunotherapy. Currently, in vitro–
cultured moDCs loaded with recombinant antigens have been used 
to vaccinate patients with chronic HBV (47, 48), HCV (49), and HIV 
(50–52) infection. These vaccines can enhance virus-specific T cell 
responses, but are hindered by the need to select appropriate anti-
gens and a GMP cell production facility to produce the vaccine. The 
production costs associated with both of these aspects are often 
not affordable for patients living in regions where such diseases are 
common. Our data suggest that it could be possible to administer 
only adjuvants or cytokines for therapeutic vaccination, relying on 
the pathogen antigen present in chronically infected patients. If we 
can optimize this approach for in vivo application, it could elimi-
nate the costly in vitro culture and selection of antigen for DC ther-
apy and lead to a new, more accessible, form of immunotherapy.
Methods
Patient PBMCs. Blood was collected from 57 chronic HBV patients at the 
Barts and the London Hospital, Azienda Ospedaliero-Universitaria di 
Parma, and the National University Hospital in Singapore. PBMCs were 
isolated by Ficoll density gradient separation and cryopreserved in liquid 
nitrogen. PBMCs from healthy donors were obtained from the Blood 
Donation Center at the National University Hospital of Singapore. All 
patients used in antigen-specific T cell assays were confirmed to be HLA-
A0201+ and HLA-Cw0801+ by molecular-based HLA typing.
FACS sorting. PBMCs were stained with HLA-DR–Alexa Fluor 700, 
CD3-FITC, CD7-FITC, CD56-FITC (eBioscience); CD14-PeCy7, CD16-
APC-H7, CD20-Horizon V450, CD11c-APC (BD Biosciences); CD141-PE 
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were washed and mixed back with remaining PBMCs and expanded in vitro 
for 10 days in Aim-V + 2% human AB serum + 20 U/ml IL-2 (R&D Systems). 
After 10 days expansion, cells were stimulated with overlapping peptide 
pools and HBV-specific T cells were quantified using IFN-γ ELISPOT. Posi-
tive responses were defined as 2 times the mean of unstimulated wells.
For autologous moDC expansion, CD14 MNs were isolated and differ-
entiated for 6 days in the conditions described above. On day 6, moDCs 
were activated with LPS and CD40L for 24 hours and then mixed with 
autologous PBMCs at a 1:10 (moDC/PBMC) ratio. Cells were incubated 
for 10 days in Aim-V 2% human AB serum + 20 U/ml IL-2. After 10 days, 
T cell responses were tested using IFN-γ ELISPOT with overlapping pep-
tides. Positive cutoff for moDC-expanded T cells was 2 times the mean of 
unstimulated wells or greater than 10 spots. When cell numbers permit-
ted, positive responses to moDC expansion were tested by intracellular 
cytokine staining for IFN-γ to confirm elispot responses.
Statistics. Statistical analysis was performed on the APC population fre-
quency in different patients categorized by viral load and liver inflamma-
tion and responses in the MLR assay using 1-way ANOVA and Tukey’s 
post-test analysis.
Study approval. All patients gave informed consent.
Note added in proof. Recent data from a phase III therapeutic vaccine trial 
showed that administering adjuvant alone (alum) led to a clinically signifi-
cant response, even better than that using alum plus HBsAg, suggesting 
that adjuvant alone is capable of inducing immunity using viral antigen 
present within the patient as a result of the chronic infection (53).
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with 5 μg/ml HBs183-91(FLLTRILTI), HBs171-80 (FLGPLLVLQA), or 
HBc18-27 (FLPSDFFPSV) peptide served as positive controls for T cell acti-
vation. IFN-γ ELISPOT was performed as described previously using 5 μg/ml 
of 1-D1K for capture and 0.5 μg/ml 7B6-1-Biotin plus streptavidin-ALP for 
detection (Mabtec) (19). ELISPOT plates were developed and analyzed using 
CTL Immunospot analyzer. Cut-off values for positive responses were set 
according to cumulative data from healthy donors and HLA-mismatched 
chronic HBV responses (data not shown). Wells were considered positive if 
responses were above 20 spot forming units/50,000 T cells.
moDC generation and cross-presentation. CD14+ MNs were isolated from 
healthy donors and chronic HBV patients by FACS sorting or positive 
selection using CD14 microbeads (greater than 90% purity; Miltenyi 
Biotec). Purified MNs were then cultured in RPMI 1640 supplemented 
with 10% heat-inactivated FBS, 20 mM HEPES, 0.5 mM sodium pyruvate, 
100 U/ml penicillin, 100 μg/ml streptomycin, MeM amino acids, Glu-
tamax, MeM nonessential amino acids, and 55 μM 2-mercaptoethanol 
(Invitrogen). GM-CSF + IL-4 moDCs were made by culturing CD14 MNs 
in 50 ng/ml (1500 U/ml) IL-4 and 50 ng/ml (750 U/ml) GM-CSF (R&D 
systems) for 6 days. GM-CSF + IL-15 (R&D Systems) moDCs were made 
by culturing CD14 MNs in 100 ng/ml (1500 U/ml) GM-CSF + 200 ng/ml 
IL-15. Half of the medium was removed after 3 days and replaced with 
complete RPMI containing cytokines. After 6 days of incubation, moDCs 
were stained with CD14-PerCp (Miltenyi Biotec), HLA-DR Alexa Fluor 
700 (eBioscience), CD80-FITC (BD Bioscience), and CD86-APC (Bioleg-
end) to confirm differentiation.
Six-day moDCs were cultured overnight in medium alone or activated 
with 10 μg/ml poly(I:C) or 0.1 μg/ml LPS (Invivogen) + 50 ng/ml soluble 
HEK-derived CD40L (R&D Systems). Following overnight incubation, 
moDCs were washed 3 times with HBSS and cocultured at a 2:1 effec-
tor/target ratio (10,000 T cells:5000 moDCs) with CD8+ HBs183-91– or 
HBs171-80–specific TCR-redirected T cells for IFN-γ ELISPOT. A cut-
off for positive response, 25 IFN-γ spots/25,000 T cells for nonactivated 
moDCs and 35 IFN-γ spots/25,000 T cells for activated moDCs, was set 
based on the cumulative data of negative controls from healthy donors and 
HLA-mismatched chronic HBV patients (Figures 5 and 6).
To test cross-presentation from healthy donors, CD14 MNs were loaded 
with HBV antigen at day 0 (HBsAg 1–20 μg/ml) for 4 hours in complete 
RPMI and then differentiated to moDCs. Following the loading incubation 
at 0 days, 50,000 CD14 MNs were stained for HBsAg to confirm uptake.
Autologous T cell expansion with moDCs. Patients PBMCs were expanded with 
synthetic 15-mer overlapping peptides as previously described (19). Briefly, 
20% of PBMCs were loaded with 10 μg/ml peptide pools covering the whole 
HBcAg and HBsAg and incubated for 1 hour at 37°C. Peptide-loaded cells 
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